| Variable . | Prior failure of 1 biologic . | Prior intolerance of 1 biologic . | Biologic naive . |
|---|---|---|---|
| Total number of patients | 650 (45.2) | 225 (15.6) | 564 (39.2) |
| Age in years, mean (SD) | 35.3 (12) | 37.1 (11.3) | 35.9 (13.5) |
| Sex male, n (%) | 282 (46) | 54 (24) | 274 (48.7) |
| Race White, n (%) | 614 (94.5) | 209 (93.1) | 493 (87.4) |
| Smoking, n (%) | 296 (45.5) | 73 (32.3) | 168 (29.7) |
| Disease duration Years, median (IQR) | 7.7 (7.4) | 9.2 (9) | 4.7 (7.6) |
| Vedolizumab, n (%) | 458 (31.8) | 161 (11.2) | 348 (24.2) |
| Ustekinumab, n (%) | 192 (13.4) | 64 (4.4) | 216 (15) |
| CRP mg/L, median (IQR) | 8.5 (17.3) | 9 (18.5) | 8.89 (20) |
| Albumin g/L, mean (SD) | 35.2 (5.4) | 35.5 (4.9) | 35.4 (5.5) |
| CDAI Score, mean (SD) | 323.2 (62.9) | 313.3 (58.7) | 307.2 (58.9) |
| Variable . | Prior failure of 1 biologic . | Prior intolerance of 1 biologic . | Biologic naive . |
|---|---|---|---|
| Total number of patients | 650 (45.2) | 225 (15.6) | 564 (39.2) |
| Age in years, mean (SD) | 35.3 (12) | 37.1 (11.3) | 35.9 (13.5) |
| Sex male, n (%) | 282 (46) | 54 (24) | 274 (48.7) |
| Race White, n (%) | 614 (94.5) | 209 (93.1) | 493 (87.4) |
| Smoking, n (%) | 296 (45.5) | 73 (32.3) | 168 (29.7) |
| Disease duration Years, median (IQR) | 7.7 (7.4) | 9.2 (9) | 4.7 (7.6) |
| Vedolizumab, n (%) | 458 (31.8) | 161 (11.2) | 348 (24.2) |
| Ustekinumab, n (%) | 192 (13.4) | 64 (4.4) | 216 (15) |
| CRP mg/L, median (IQR) | 8.5 (17.3) | 9 (18.5) | 8.89 (20) |
| Albumin g/L, mean (SD) | 35.2 (5.4) | 35.5 (4.9) | 35.4 (5.5) |
| CDAI Score, mean (SD) | 323.2 (62.9) | 313.3 (58.7) | 307.2 (58.9) |
| Variable . | Prior failure of 1 biologic . | Prior intolerance of 1 biologic . | Biologic naive . |
|---|---|---|---|
| Total number of patients | 650 (45.2) | 225 (15.6) | 564 (39.2) |
| Age in years, mean (SD) | 35.3 (12) | 37.1 (11.3) | 35.9 (13.5) |
| Sex male, n (%) | 282 (46) | 54 (24) | 274 (48.7) |
| Race White, n (%) | 614 (94.5) | 209 (93.1) | 493 (87.4) |
| Smoking, n (%) | 296 (45.5) | 73 (32.3) | 168 (29.7) |
| Disease duration Years, median (IQR) | 7.7 (7.4) | 9.2 (9) | 4.7 (7.6) |
| Vedolizumab, n (%) | 458 (31.8) | 161 (11.2) | 348 (24.2) |
| Ustekinumab, n (%) | 192 (13.4) | 64 (4.4) | 216 (15) |
| CRP mg/L, median (IQR) | 8.5 (17.3) | 9 (18.5) | 8.89 (20) |
| Albumin g/L, mean (SD) | 35.2 (5.4) | 35.5 (4.9) | 35.4 (5.5) |
| CDAI Score, mean (SD) | 323.2 (62.9) | 313.3 (58.7) | 307.2 (58.9) |
| Variable . | Prior failure of 1 biologic . | Prior intolerance of 1 biologic . | Biologic naive . |
|---|---|---|---|
| Total number of patients | 650 (45.2) | 225 (15.6) | 564 (39.2) |
| Age in years, mean (SD) | 35.3 (12) | 37.1 (11.3) | 35.9 (13.5) |
| Sex male, n (%) | 282 (46) | 54 (24) | 274 (48.7) |
| Race White, n (%) | 614 (94.5) | 209 (93.1) | 493 (87.4) |
| Smoking, n (%) | 296 (45.5) | 73 (32.3) | 168 (29.7) |
| Disease duration Years, median (IQR) | 7.7 (7.4) | 9.2 (9) | 4.7 (7.6) |
| Vedolizumab, n (%) | 458 (31.8) | 161 (11.2) | 348 (24.2) |
| Ustekinumab, n (%) | 192 (13.4) | 64 (4.4) | 216 (15) |
| CRP mg/L, median (IQR) | 8.5 (17.3) | 9 (18.5) | 8.89 (20) |
| Albumin g/L, mean (SD) | 35.2 (5.4) | 35.5 (4.9) | 35.4 (5.5) |
| CDAI Score, mean (SD) | 323.2 (62.9) | 313.3 (58.7) | 307.2 (58.9) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
